Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 4/4)
유사 논문P · Population 대상 환자/모집단
37 patients who reduced from 100 mg to 50 mg, 35/37 (94.
I · Intervention 중재 / 시술
Efficacy and safety of 50 mg
C · Comparison 대조 / 비교
100 mg daily frontline dasatinib therapy in chronic
O · Outcome 결과 / 결론
[CONCLUSION] Dasatinib 50 mg daily demonstrates non-inferior efficacy and superior safety compared to 100 mg, particularly in reducing pleural effusion risk. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15719-7.
[BACKGROUND] There is an increasing movement among chronic myeloid leukemia (CML) patients towards optimizing dosages and implementing personalized treatment plans.
- HR 1.59
APA
Cheng F, Wang F, et al. (2026). Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.. BMC cancer, 26(1). https://doi.org/10.1186/s12885-026-15719-7
MLA
Cheng F, et al.. "Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.." BMC cancer, vol. 26, no. 1, 2026.
PMID
41668074
Abstract
[BACKGROUND] There is an increasing movement among chronic myeloid leukemia (CML) patients towards optimizing dosages and implementing personalized treatment plans.
[METHODS] We conducted a non-randomized, non-controlled, observational cohort analysis to evaluate the efficacy and safety of first-line dasatinib treatment for CML, and compare the differences between low-dose dasatinib (50 mg daily) and standard-dose dasatinib (100 mg daily).
[RESULTS] No significant baseline differences in age, sex, Sokal risk, or ELTS scores were observed. The 100 mg group had longer median treatment duration (56.1 vs. 30.3 months, < 0.001) and lower rates of sustained first-line therapy (61.3% vs. 95.6%, < 0.001). Both doses achieved comparable 12-month cumulative CCyR (100 mg: 83.5% vs. 50 mg: 93.2%, = 0.25), MMR (58.3% vs. 59.1%, = 0.94), MR4 (34.0% vs. 25.0%, = 0.24), MR4.5 (23.3% vs.13.6%, = 0.16), and 2-year EFS (86.3% vs. 91.1%; HR = 1.59, 95% CI = 0.69–3.64, = 0.33). Time to response milestones (CCyR, MR4, DMR) showed no statistical difference. The 50 mg group had significantly lower pleural effusion incidence (2.2% vs. 25.2%, < 0.001). No differences in hematologic or most non-hematologic AEs were observed. Among 37 patients who reduced from 100 mg to 50 mg, 35/37 (94.6%) maintained or deepened responses. Notably, 13 patients with MMR attained DMR post-reduction.
[CONCLUSION] Dasatinib 50 mg daily demonstrates non-inferior efficacy and superior safety compared to 100 mg, particularly in reducing pleural effusion risk.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15719-7.
[METHODS] We conducted a non-randomized, non-controlled, observational cohort analysis to evaluate the efficacy and safety of first-line dasatinib treatment for CML, and compare the differences between low-dose dasatinib (50 mg daily) and standard-dose dasatinib (100 mg daily).
[RESULTS] No significant baseline differences in age, sex, Sokal risk, or ELTS scores were observed. The 100 mg group had longer median treatment duration (56.1 vs. 30.3 months, < 0.001) and lower rates of sustained first-line therapy (61.3% vs. 95.6%, < 0.001). Both doses achieved comparable 12-month cumulative CCyR (100 mg: 83.5% vs. 50 mg: 93.2%, = 0.25), MMR (58.3% vs. 59.1%, = 0.94), MR4 (34.0% vs. 25.0%, = 0.24), MR4.5 (23.3% vs.13.6%, = 0.16), and 2-year EFS (86.3% vs. 91.1%; HR = 1.59, 95% CI = 0.69–3.64, = 0.33). Time to response milestones (CCyR, MR4, DMR) showed no statistical difference. The 50 mg group had significantly lower pleural effusion incidence (2.2% vs. 25.2%, < 0.001). No differences in hematologic or most non-hematologic AEs were observed. Among 37 patients who reduced from 100 mg to 50 mg, 35/37 (94.6%) maintained or deepened responses. Notably, 13 patients with MMR attained DMR post-reduction.
[CONCLUSION] Dasatinib 50 mg daily demonstrates non-inferior efficacy and superior safety compared to 100 mg, particularly in reducing pleural effusion risk.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15719-7.
같은 제1저자의 인용 많은 논문 (5)
- Round versus Anatomical Implants in Primary Cosmetic Breast Augmentation: A Meta-Analysis and Systematic Review.
- Effects and Safety of Botulinum Toxin Injection in Treatment of Androgenetic Alopecia: A Meta-analysis and Systematic Review.
- Machine learning-based prognostic model of stemness and angiogenesis-related genes for predicting prognosis and immune infiltration in patients with HCC.
- Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis.
- Safety and Efficacy of Flumatinib in Patients with Chronic Phase Chronic Myeloid Leukemia: A Real-Life Cohort Observational Study.